Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte J J, Font F, Acosta C J, Schellenberg D M, Galindo C M, Kimario J, Urassa H, Brabin B, Smith T A, Kitua A Y, Tanner M, Alonso P L
Unidad de Epidemiologia y Bioestadistica, Hospital Clinic, Barcelona, Spain.
Lancet. 1997 Sep 20;350(9081):844-50. doi: 10.1016/S0140-6736(97)04229-3.
Malaria and anaemia, especially that due to iron deficiency, are two leading causes of morbidity worldwide. Little is known about the relative contribution of Plasmodium falciparum infection and iron deficiency to the aetiology of anaemia in malaria-endemic areas. We undertook a randomised comparison of different strategies for control of anaemia and malaria in infants, including an assessment of the effect of iron supplementation on malaria susceptibility.
832 infants born at one hospital in a malaria-hyperendemic area of Tanzania between January and October, 1995, were randomly assigned to group DI, receiving daily oral iron (2 mg/kg daily) plus weekly Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone); group IP, receiving iron plus weekly placebo; group DP, receiving daily placebo plus weekly Deltaprim; or group PP. supplementation was given from 8 to 24 weeks of age, and the weekly chemoprophylaxis from 8 to 48 weeks. The frequency of severe anaemia (packed-cell volume < 25%) and malaria episodes was assessed through a combination of passive case detection and cross-sectional surveys.
The groups that received iron supplementation had a lower frequency of severe anaemia than those that did not receive iron (0.62 vs 0.87 cases per person-year; protective efficacy 28.8% [95% CI 6.3-45.8). Iron supplementation had no effect on the frequency of malaria (0.87 vs 1.00 cases per person-year; protective efficacy 12.8% [-12.8 to 32.5]). The groups that received malaria prophylaxis had lower frequencies of both severe anaemia (0.45 vs 1.04 episodes per person-year; protective efficacy 57.3% [43.0-67.9]) and malaria (0.53 vs 1.34 episodes per person-year; protective efficacy 60.5% [48.2-69.9]) than the groups that did not receive prophylaxis. After the end of the intervention period, children who had received malaria chemoprophylaxis had higher rates of severe anaemia and malaria than non-chemoprophylaxis groups (relative risks 2.2 [1.3-3.7] and 1.8 [1.3-2.6]).
Malaria chemoprophylaxis during the first year of life was effective in prevention of malaria and anaemia but apparently impaired the development of natural immunity. Iron supplementation was effective in preventing severe anaemia without increasing susceptibility to malaria. Our findings support iron supplementation of infants to prevent iron-deficiency anaemia, even in malaria-endemic areas.
疟疾和贫血,尤其是缺铁性贫血,是全球发病的两大主要原因。关于恶性疟原虫感染和缺铁在疟疾流行地区贫血病因中的相对作用,人们了解甚少。我们对婴儿贫血和疟疾控制的不同策略进行了随机比较,包括评估铁补充剂对疟疾易感性的影响。
1995年1月至10月在坦桑尼亚疟疾高度流行地区的一家医院出生的832名婴儿被随机分为四组:DI组,每日口服铁剂(2毫克/千克/日)加每周一次的复方磺胺多辛(3.125毫克乙胺嘧啶加25毫克氨苯砜);IP组,铁剂加每周一次安慰剂;DP组,每日安慰剂加每周一次复方磺胺多辛;或PP组。从8周龄至24周龄给予补充剂,每周化学预防从8周龄至48周龄。通过被动病例检测和横断面调查相结合的方式评估严重贫血(红细胞压积<25%)和疟疾发作的频率。
接受铁补充剂的组严重贫血的频率低于未接受铁剂的组(0.62例/人年对0.87例/人年;保护效力28.8%[95%可信区间6.3 - 45.8])。铁补充剂对疟疾频率没有影响(0.87例/人年对1.00例/人年;保护效力12.8%[-12.8至32.5])。接受疟疾预防的组严重贫血(0.45次发作/人年对1.04次发作/人年;保护效力57.3%[43.0 - 67.9])和疟疾(0.53次发作/人年对1.34次发作/人年;保护效力60.5%[48.2 - 69.9])的频率均低于未接受预防的组。在干预期结束后,接受疟疾化学预防的儿童严重贫血和疟疾的发生率高于未进行化学预防的组(相对危险度分别为2.2[1.3 - 3.7]和1.8[1.3 - 2.6])。
生命第一年进行疟疾化学预防对预防疟疾和贫血有效,但显然损害了自然免疫力的发展。铁补充剂在预防严重贫血方面有效,且不会增加对疟疾的易感性。我们的研究结果支持对婴儿补充铁剂以预防缺铁性贫血,即使在疟疾流行地区也是如此。